Home » Annual mammography from age 40: minimal risks and maximum reduction in mortality

Annual mammography from age 40: minimal risks and maximum reduction in mortality

by admin
Annual mammography from age 40: minimal risks and maximum reduction in mortality

Having breast cancer screening annually, from age 40 to age 79, results in the greatest reduction in mortality with minimal risks. This was revealed by a new study published in Radiology, journal of the Radiological Society of North America. Breast cancer is the second leading cause of cancer death among women in the United States. Although research shows that consistent participation in mammography screening can reduce breast cancer deaths by 40%, only 50% or less of eligible women actually participate in annual screening.

Mammography at age 40 in the USA. What’s happening in Italy’s regions by Elvira Naselli 10 May 2023

“There is an ongoing debate about recommendations for breast cancer screening, particularly when to start and how often to screen,” she said. Debra L. Monticcioloprofessor of radiology at Dartmouth Geisel School of Medicine in Hanover, New Hampshire and principal investigator.
“A 2009 U.S. Preventive Services Task Force recommendation that people get screened every two years, or biennially, starting at age 50 resulted in a decline in screening participation nationwide,” Monticciolo said. Breast cancer: healthy lifestyles reduce the risk of developing the disease by 27% by Irma D’Aria 07 July 2023 The USPSTF has drawn up new recommendations in 2023, suggesting that women undergo biannual screening between the ages of 40 and 74 . The American College of Radiology, the Society of Breast Imaging and the National Comprehensive Cancer Network recommend annual screening for women at average risk for breast cancer, starting at age 40 and as long as the woman is in good health. In the study, Monticciolo and colleagues performed a secondary analysis of median breast cancer screening outcome estimates for 2023 from the Cancer Intervention and Surveillance Modeling Network. CISNET modeling data provided researchers with the opportunity to estimate screening outcomes at various frequencies and ages of initiation. Artificial intelligence will read mammograms (but not alone) by Roberta Villa 04 August 2023 Researchers compared the benefits of screening, including reduction in mortality, years of life gained, deaths from breast cancer avoided, and its risks, including benign, or unnecessary, biopsies, and recall rates for four different scenarios: biannual screening of women ages 50 to 74, the long-standing USPSTF recommendation, biannual screening of women ages 40 to 74 years, the task force’s new draft recommendation, annual screening between ages 40 and 74, and annual screening between ages 40 and 79. CISNET does not allow modeling beyond age 79. Mammography, if done regularly, can reduce mortality by 66% by Barbara Orrico 01 December 2023 The review of CISNET estimates found that annual screening between the ages of 40 and 79, with digital mammography or tomosynthesis, led to a reduction in mortality by 41.7%. Biennial screening between 50 and 74 years of age and 40 and 74 years of age resulted in a reduction in mortality of 25.4% and 30% respectively. Annual screening among women aged 40 to 79 years showed the lowest rate of false-positive mammography, at 6.5%, and benign biopsies, at 0.88%, compared to other scenarios screening. Cancers, 18 thousand more new cases in three years and screening down by 3% by Irma D’Aria 12 December 2023

“The most important takeaway from our study is that annual screening, starting at age 40 and continuing until at least age 79, offers the highest mortality reduction, the greatest number of cancer deaths averted, and the greatest number of years of life earned – explained Monticciolo – there is an enormous benefit in annual screening up to at least 79 years of age and the benefit is even greater if women are subjected to screening beyond the age of 79”. Each of her has her own mammogram by Tiziana Moriconi 19 January 2024

See also  The new electronic health file arrives, agreed between the State and the Regions - Health

“Although the USPSTF uses CISNET modeling to make its recommendations, it refers to recall rates and benign biopsies as harms, rather than risks,” he said. “To balance the harms and benefits of screening mammography, they are willing to give up some mortality benefit to prevent women from being recalled for additional imaging tests and benign biopsies.” Targeted screening and early diagnosis: this is how AI is changing medicine by Sandro Iannaccone 02 February 2024

According to the researchers’ analyses, the likelihood of a woman having a benign biopsy following annual screening is less than 1 percent, and all recall rates for screening mammography are less than 10 percent. When screening is performed annually with tomosynthesis, the recall rate drops to 6.5%. “The risks of screening are not lethal and are manageable for most women – Monticciolo further observed – but advanced breast cancer is often lethal”.
“Breast cancer is easier to treat if it is discovered earlier: we can save women from additional surgery and chemotherapy – she specified – it is simply a better idea to move to early diagnosis, and this is what screening does.”

Mortality benefits

“I hope that the study adds to the literature that supports annual screening starting from the age of 40 as the best way to diagnose cancer early – argued Monticciolo – this research is important because it demonstrates once again that annual screening between the ages of 40 and 79 years brings a huge increase in benefits in terms of mortality and that the chances of suffering harm are low for every single test. It’s about giving value to women’s lives. I hope that GPs realize that the risks of screening they are manageable and the benefits are enormous. We need to do it for women,” she concluded.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy